Last reviewed · How we verify
ASCT conditioning
ASCT conditioning is a high-dose chemotherapy regimen used to prepare the bone marrow for autologous stem cell transplantation by eliminating malignant cells and creating space for donor stem cells to engraft.
ASCT conditioning is a high-dose chemotherapy regimen used to prepare the bone marrow for autologous stem cell transplantation by eliminating malignant cells and creating space for donor stem cells to engraft. Used for Multiple myeloma, Lymphoma (Hodgkin and non-Hodgkin), Leukemia.
At a glance
| Generic name | ASCT conditioning |
|---|---|
| Also known as | THAM or BEAM |
| Sponsor | Prof. Dr. M. Dreyling (co-chairman) |
| Drug class | High-dose chemotherapy conditioning regimen |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
ASCT (autologous stem cell transplant) conditioning typically involves high-dose chemotherapy agents, often including alkylating agents and/or total body irradiation, designed to ablate the patient's bone marrow and eliminate disease burden. This creates an immunologic and physical space for reinfusion of the patient's own previously harvested hematopoietic stem cells, which then reconstitute the bone marrow and immune system.
Approved indications
- Multiple myeloma
- Lymphoma (Hodgkin and non-Hodgkin)
- Leukemia
- Other hematologic malignancies
Common side effects
- Mucositis
- Neutropenia
- Thrombocytopenia
- Infection
- Nausea and vomiting
- Hepatic toxicity
- Renal toxicity
- Secondary malignancy
Key clinical trials
- ASCT With TEAM Conditioning for Lymphoma With High Risk of CNS Relapse (PHASE2)
- A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma (PHASE3)
- A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy (PHASE3)
- Comparison of ASCT and Conventional Chemotherapy in High Risk Waldenström Macroglobulinemia (PHASE4)
- Efficacy of Upfront and Maintenance Obinutuzumab in Mantle Cell Lymphoma Treated by DHAP and MRD Driven Maintenance (PHASE2)
- Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma (PHASE2)
- Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma (PHASE2)
- Daratumumab After Stem Cell Transplant in Treating Patients With Multiple Myeloma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ASCT conditioning CI brief — competitive landscape report
- ASCT conditioning updates RSS · CI watch RSS
- Prof. Dr. M. Dreyling (co-chairman) portfolio CI